Free Trial
NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

Amylyx Pharmaceuticals logo
$7.32 +0.09 (+1.17%)
As of 10:51 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Key Stats

Today's Range
$7.13
$7.38
50-Day Range
$4.35
$7.24
52-Week Range
$1.69
$7.40
Volume
196,081 shs
Average Volume
1.20 million shs
Market Capitalization
$652.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Moderate Buy

Company Overview

Amylyx Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

AMLX MarketRank™: 

Amylyx Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 341st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amylyx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amylyx Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Amylyx Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($1.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amylyx Pharmaceuticals is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amylyx Pharmaceuticals is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Amylyx Pharmaceuticals has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Amylyx Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.19% of the float of Amylyx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Amylyx Pharmaceuticals has recently decreased by 2.18%, indicating that investor sentiment is improving.
  • Dividend Yield

    Amylyx Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Amylyx Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.19% of the float of Amylyx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Amylyx Pharmaceuticals has recently decreased by 2.18%, indicating that investor sentiment is improving.
  • News Sentiment

    Amylyx Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    11 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amylyx Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amylyx Pharmaceuticals' insider trading history.
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
AMLX Amylyx Pharmaceuticals, Inc. - Seeking Alpha
13 Best Biotech Stocks To Invest In Now
See More Headlines

AMLX Stock Analysis - Frequently Asked Questions

Amylyx Pharmaceuticals' stock was trading at $3.78 at the start of the year. Since then, AMLX stock has increased by 91.5% and is now trading at $7.24.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.03.
Read the conference call transcript
.

Amylyx Pharmaceuticals (AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share.

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/08/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMLX
CIK
1658551
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$4.00
Potential Upside/Downside
+51.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$301.74 million
Pretax Margin
-345.81%

Debt

Sales & Book Value

Annual Sales
$87.37 million
Price / Cash Flow
N/A
Book Value
$2.40 per share
Price / Book
3.02

Miscellaneous

Free Float
78,712,000
Market Cap
$645.37 million
Optionable
Optionable
Beta
-0.49
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:AMLX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners